Gilead Sciences
Gilead Foundation awards $6.5m in grants to support STEM education
September 26, 2025Research and Development Funding and Investment, Gilead Sciences, stem
Gilead Sciences has committed over $6.5m in grant funding towards improving science, technology, engineering and maths (STEM) education, the company …
Gilead’s Veklury recommended by NICE for COVID-19 treatment
April 9, 2024Medical Communications COVID-19, Gilead Sciences, Infections and infestations, remdesivir
Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has recommended the use of Veklury …
Gilead and Merck share data from phase 2 trial of HIV treatment
March 7, 2024Research and Development Gilead Sciences, HIV, HIV/AIDS, Merck, clinical trials
Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced results from the phase 2 …
Gilead and Compugen enter exclusive license agreement for immunotherapy programme
December 20, 2023Research and Development Gilead Sciences, Immunology, License Agreement, compugen, immunology
Gilead Sciences and Compugen have announced that they have entered an exclusive license agreement for Compugen’s potential first in class, …
Nimbus Therapeutics receives $200 million payment from Gilead
November 2, 2016Research and Development Gilead Sciences, Nimbus Therapeutics, nash
Nimbus Therapeutics only signed a deal with Gilead Sciences back in April of this year and yet have already received …
Gilead’s drug boosted by positive Phase II trials and aims to move forward
October 21, 2016Medical Communications Gilead, Gilead Sciences, clinical trials, fatty liver disease
Gilead Sciences has announced positive results from three Phase II studies upon their drug GS-4997, otherwise known as selonsertib. The …
Gilead Sciences says Phase III trials for chronic HBV drug meet primary endpoints
April 15, 2016Gilead Sciences, US FDA, chronic hepatitis B, drug trial
Biotech firm Gilead Sciences (NYSE: GILD) on Friday announced positive results from late-stage trials for its drug to treat chronic …
Gilead to buy Nimbus Therapeutics’ unit, trial drug for up to $1.2 billion
April 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Gilead Sciences, M&A, MA, Nimbus Apollo, Nimbus Therapeutics, merger and acquisitions
Gilead Sciences (Nasdaq: GILD) has agreed to buy a unit of biotechnology firm Nimbus Therapeutics and its trial drug to …
Gilead must pay MSD $200m in hep C drug patent case
March 29, 2016Manufacturing and Production, Sales and Marketing Gilead Sciences, MSD, Solvadi, harvoni
A Californian federal jury has ordered Gilead Sciences to pay MSD and Ionis $200 million for infringing on patents relating …
Gilead cancer boss departs after safety concerns halt Zydelig trials
March 18, 2016Medical Communications, Research and Development Gilead Sciences, zydelig
In the wake of the halting of six clinical trials of its blood cancer drug Zydelig due to safety concerns, …
EMA starts review of Gilead Sciences’ Zydelig following safety concerns
March 14, 2016Research and Development, Sales and Marketing EMA, Gilead Sciences, blood cancer, clinical trials, zydelig
Regulators in Europe have initiated a safety review of Gilead Sciences’ (Nasdaq: GILD) blood cancer drug Zydelig (idelalisib) following reports …
FDA approves Gilead’s Odefsey for treatment of HIV-1 infection
March 2, 2016Research and Development, Sales and Marketing Gilead Sciences, HIV, Odefsey
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has approved its TAF-based single tablet regimen Odefsey …
Positive CHMP opinion for Gilead’s Descovy
February 26, 2016Research and Development Gilead Sciences
The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the EMA, has adopted a positive opinion …
Gilead announces HIV regimen trial results
February 25, 2016Medical Communications, Research and Development, Sales and Marketing Gilead Sciences
Gilead Sciences has reported 48-week Phase III trial results suggesting fixed-dose Emtriva and tenofovir alafenamide (F/TAF) combinations matched its Truvada …
FDA approves Gilead’s Harvoni in two new indications
February 18, 2016Research and Development Gilead Sciences, MSD, harvoni, hepatitis C
The hepatitis C treatment battle had its latest development yesterday, with the FDA awarding Gilead Science’s market-leading drug Harvoni (ledipasvir/sofosbuvir) …
